At HistologiX, no biomarker is too much trouble. Working with a proactive and flexible approach, we’re able to accommodate novel targets as well as those already well defined. We can advise on and source appropriate antibody and control tissue for your species and tissue of interest, or work with your own. With a combination of experienced scientists and a wide range of automated platforms, we pride ourselves on developing both chromogenic and immunofluorescent assays with outstanding standardisation and repeatability.
Our inhouse panel of chromogenic and immunofluorescent assays has been optimised for a range of biomarkers and for use on different tissue types (including xenografts, FFPE and frozen) and species.
We use dual chromogenic and multiplex immunofluorescent capabilities to identify multiple targets/biomarkers within one tissue section. In addition to our growing list of validated assays, our experienced scientists routinely develop custom chromogenic and immunofluorescent assays with outstanding standardisation and repeatability. We also offer Ultivue and RNA scope to further characterise your samples.
We carry out assay transfers and optimisations, antibody and target selection studies, assay repeatability studies and tissue screening using TMAs. We assist with study design and can advise on and source appropriate antibody and control tissue for your species and tissue of interest. We work with a variety of automated platforms, all validated for use in GLP/GCP studies and offering enhanced repeatability.
Our cellular pathology team can support you from your research phase to preclinical testing through to clinical research. We can help you: visualise cell types and reporter gene product (e.g. GFP); detect and quantify proliferating cells, immune and inflammatory cells, plus apoptotic cells; assess up/downregulation of markers of interest in different disease states or treatment regimens and support patient stratification and the identification of predictive and prognostic markers.
We have a catalogue of chromogenic and immunofluorescent assays developed in house and optimised for range of biomarkers. These are available on a range of tissue types (different species even xenografts, FFPE and frozen). Our dual chromogenic and multiplex immunofluorescent capabilities to identify multiple targets/biomarkers within one section.
Our automated platforms are validated for use in GLP/GCP studies, allowing us to provide enhanced repeatability. These platforms include Ventana’s Benchmark Ultra and Discovery Ultra, Leica’s Bond Rx, Hamamatsu’s NanoZoomer 2.0, and Zeiss’s AxioScan Z.1.
Assay transfers and optimisations
We perform assay development and optimisations on your target of interest. In addition we can transfer assays from your lab to ours for further development and validation. With this we support antibody and target selection studies along with distribution studies.
Tissue Microarrays (TMAs)
We routinely use TMAs in a range of studies such as distribution studies to evaluate protein and mRNA expression, as well as for non-regulatory screening to identify suitable monoclonal antibody clones. These can also be used for assessing cancer biomarkers in a variety of defined cancers.
Study design and control tissue sourcing
Our technical team can help support you with your study design, from preclinical work through to clinical trials. We also have extensive expertise in sourcing and advising on the relevant control tissue.